Compugen Ltd. (NASDAQ:CGEN) Q1 2023 Earnings Conference Call May 15, 2023 8:30 AM ET

Company Participants

Yvonne Naughton - Head of Investor Relations and Corporate Communications

Anat Cohen-Dayag - President and Chief Executive Officer

Alberto Sessa - Chief Financial Officer

Henry Adewoye - Chief Medical Officer

Eran Ophir - Senior Vice President, Research and Drug Discovery

Conference Call Participants

Mark Breidenbach - Oppenheimer & Co. Inc.

Stephen Willey - Stifel Financial Corp.

Asthika Goonewardene - Truist Securities

Daina Graybosch - SVB Securities

Operator

Ladies and gentlemen, thank you for joining us today. Welcome to Compugen’s First Quarter 2023 Results Conference Call. At this time, all participants are in a listen-only mode. An audio webcast of this call is available in the Investors section of Compugen’s website, www.cgen.com. As a reminder, today’s call is being recorded.

I would now like to introduce, Yvonne Naughton, Head of Investor Relations and Corporate Communications. Yvonne, please go ahead.

Yvonne Naughton

Thank you, operator, and thank you all for joining us on the call today. Joining me for Compugen for the prepared remarks are Dr. Anat Cohen-Dayag, President and Chief Executive Officer; and Alberto Sessa, Chief Financial Officer. Dr. Henry Adewoye, Chief Medical Officer; and Dr. Eran Ophir, Senior Vice President Research and Drug Discovery will join us for the Q&A.

Before we begin, we would like to remind you that during this call, the company may make projections or forward-looking statements regarding future events, business outlook, development efforts and their potential outcome, the company’s discovery platform, anticipated progress and plans, results and timelines for its programs, financial and accounting related matters, as well as statements regarding the company’s future cash position. We wish to caution you that such statements reflect only the company’s current beliefs, expectations and assumptions, but actual results, performance or achievements of the company may differ materially. These statements are subject to known and unknown risks and uncertainties and we refer you to the SEC filings for more details on these risks, including the company’s most recent annual report on Form 20-F, filed with the SEC on February 28, 2022. The company undertakes no obligation to update projections and forward-looking statements in the future.

And now, I’ll turn the call over to Anat.

Anat Cohen-Dayag

Thank you, Yvonne. Good morning and good afternoon, everyone, and welcome to our first quarter 2023 update. At Compugen, we are advancing a differentiated clinical strategy evaluating a drug combination that was never tested before in a space, where there is a significant unmet need and potential opportunity to transform the lives of cancer patients with the right immunotherapy combination.